diabetes

The program will support Johns Hopkins' research into saliva testing and diagnostics and will help GBS form its commercialization strategy for two saliva-based tests.

For the first time, WHO's essential diagnostics list includes tests that it recommends should also not be supplied because they are unreliable, among other reasons.

Though its point-of-care revenues fell, the firm's clinical laboratory sales for the third quarter rose 44 percent over the prior-year quarter

The ELISA-based test, which has CE marking, uses protein signatures in blood to detect the onset of kidney disease in type 2 diabetics.

The companies are currently working together to commercialize their respective products including genetic tests for type 2 diabetes and gestational diabetes risk.

KidneyIntelX is designed to help assess the risk of progressive decline in kidney function in patients with type 2 diabetes and chronic kidney disease.

The company said it is developing a rapid COVID-19 antibody test that will provide results in 12 minutes using a finger prick of blood.

KidneyIntelX can be used to report risk assessment results for fast-progressing kidney disease and future kidney failure for patients with chronic kidney disease.

The point-of-care system is designed to measure glycated hemoglobin levels in whole blood for use in the monitoring and management of diabetes.

Emergency testing related to the SARS-CoV-2 pandemic strongly increased, but routine testing declined due to fewer regular health checks.